Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)

HIV Medicine

Volumn 12, Issue 7, 2011, Pages 438-441

  Saumoy, M ^a   Tiraboschi, Jm ^a   Gutierrez, M ^b   Niubo J ^c   Domingo, P ^b   Vila, A ^a   Podzamczer, D ^a  

^a Bellvitge University Hospital   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cerebrospinal fluid; Fosamprenavir ritonavir; Monotherapy; Reservoirs; Semen

Indexed keywords

AMPRENAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIQUID CHROMATOGRAPHY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CARBAMATES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHOSPHORIC ACID ESTERS; PILOT PROJECTS; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SPECTRUM ANALYSIS; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 79959983491     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00898.x     Document Type: Article

References (19)

1. Arribas JR, Delgado R, Arranz A et al. Lopinavir-ritonavir monotherapy vs. lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51: 147-152.
2. Katlama C, Valantin MA, Algarte-Genin M et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365-2374.
3. Arribas JR, Horban A, Gerstoft J et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50copies/ml. AIDS 2010; 24: 223-230.
4. Rieger A, Banhegyi D, Schmidt W et al. The MONET trial 96 week analysis: darunavir/ritonavir monotherapy vs. DRV/r+2 NRTIs, for patients with HIV RNA <50copies/mL at baseline. 18th International AIDS Conference. Vienna, July 2010 [Abstract THLBB209].
5. Gutmann C, Cusini A, Günthard HF et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24: 2347-2354.
6. Karlström O, Josephson F, Sönnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44: 417-422.
7. Wilkin TJ, McKinnon JE, DiRienzo AG et al. Regimen simplification to Atazanavir-Ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199: 866-871.
8. Capparelli EV, Holland D, Okamoto C et al. Lopinavir concentrations in cerebrospinal fluid exceeds the 50% inhibitory concentration for HIV. AIDS 2005; 19: 949-952.
9. Yilmaz A, Izadkhashti A, Price RW et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25: 457-461.
10. Letendre S, Best B, Rossi S et al. Therapeutic amprenavir and abacavir concentrations in CFS from the same individuals. 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, Netherlands, April 2009 [Abstract P-18].
11. Best BM, Letendre SL, Brigid E et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23: 83-87.
12. Vernazza P, Daneel S, Schiffer V et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) trial. AIDS 2007; 21: 1309-1315.
13. Ghosn J, Chaix M-L, Peytavin G et al. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J Antimicrob Chemother 2008; 61: 1344-1347.
14. Eron JJ, Smeaton LM, Fiscus SA et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). J Infect Dis 2000; 181: 1622-1628.
15. Lambert-Niclot S, Duvivier C, Algarte-Genin M et al. Darunavir concentrations in seminal plasma in patients receiving darunavir/ritonavir monotherapy: A MONOI-ANRS 136 Substudy. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract QJ;#610].
16. Knobel H, Alonso J, Casado JL et al. Validation of simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16: 605-613.
17. Gathe JC, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir vs. twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18: 1529-1537.
18. Sale M, Sadler BM, Stein DS. Pharmacokinetic modelling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46: 746-754.
19. Pulido F, Pérez-Velero I, Delgado R et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14: 195-201.